China, Nov. 3 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A single-arm, multi-center Phase III clinical trial to evaluate the diagnostic efficacy, pharmacokinetics and safety of copper [64Cu] oxytreotide injection PET/CT for somatostatin receptor-positive neuroendocrine tumors (NETs)'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600135815
Registration Time: 2026/11/02
Type: Interventional study
Primary Sponsor: Fudan University Shanghai Cancer Center
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=324829
Published by HT Digital Content Services with permission from Health Daily Digest....